Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule
Inside information Nanoform Finland Plc October 20[th], 2020 at 5:15 p.m. Finnish time Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company will, in the fourth quarter of 2020, start the first ever human trial of a drug candidate nanoformed using Nanoform’s proprietary CESS[®] technology. Dosing will begin before year-end[ ]2020 (previously: in 2021) and results are expected before the end of Q2/2021. The clinical